ClinicalTrials.gg
CompletedNCT04057729Updated Mar 30, 2020

IMP4297 Food Effect Trial in Healthy Volunteers

A Phase 1 interventional study of IMP4297 in Solid Tumor, sponsored by Impact Therapeutics, Inc.. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-30.

Sponsored by Impact Therapeutics, Inc. · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A phase I, single-site, open-label, randomized, single-dose, two-way crossover study to evaluate the effect of food on the pharmacokinetic characteristics of IMP4297 capsules in China

Read the detailed description

This food-effect study plans to enroll 16 (at least 12 to complete the study) subjects. Subjects will be randomly assigned to 1 of 2 dosing sequences (fasted or standard high-fat breakfast) at a 1:1 ratio generated from a computer. Each dosing sequence will consist of 2 cycles, with 1 dose in each cycle of the study and a washout period of at least 7 days between each dose. Study drug will be administered to subjects in the morning of each administration day of each cycle. PK, ECG, vital signs, physical examinations and laboratory tests will be performed as specified in the protocol. Tolerability and safety of the treatment will be evaluated by monitoring adverse events.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Impact Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must fully understand the purpose, nature, methods of the trial and possible adverse reactions and volunteer as a subject. Subjects have to sign themselves prior to any study-related procedures and ensure that any procedure would involve themselves in the study.
  2. Chinese male subjects aged 18 to 55 years (inclusive) at screening.
  3. Have (BMI) between 19.0 and 26.0 kg/m2 (inclusive), and body weight≥50.0 kg.
  4. Detailed medical history, vital signs (blood pressure, pulse and body temperature), comprehensive physical examination, laboratory tests (blood routine, blood biochemistry and urine routine), 12-lead (ECG) and other test results show no abnormality or without clinical significance if abnormal.
  5. Have no plan of giving birth and be willing to use effective ; and have no plan to donate sperm during the study and 90 days after the last dose of the drug. Non-drug contraception should be used during the trial voluntarily.
  6. Be able to communicate well with the investigator, understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Have clinical abnormalities to be excluded, including but not limited to disorders of the nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bone and other systemic diseases.
  2. Have a history of allergic disease (including drug allergies, allergic reactions to two or more foods).
  3. Have a history of dysphagia or any gastrointestinal disorder affecting drug absorption.
  4. Have had surgery within 3 months prior to screening or have scheduled surgery during the study, and have had surgery which may affect the absorption, distribution, metabolism and excretion of drugs.
  5. Inability to tolerate venipuncture, have fear of needles and have a history of hemophobia.
  6. Have lactose intolerance (who have had diarrhea after drinking milk).
  7. History of drug abuse within 6 months prior to screening or a positive result on urine drug screen (baseline period).
  8. History of using narcotic drugs within 3 months prior to screening.
  9. Who intake more than 14 units of alcohol per week within 3 months prior to screening (1 unit of alcohol= 360 mL of beer, 150 mL of wine or 45 mL of liquor), or have positive result in alcohol breath test (baseline period), or patients who cannot abstain from alcohol during the trial.
  10. Who smoke more than 5 cigarettes per day within 3 months prior to screening or have positive results in urine nicotine screening test (screening period or baseline period) or unable to stop using any tobacco products during the trial.
  11. Excessive consumption of tea, coffee and/or caffeine-rich beverages (more than 8 cups per day, 1 cup = 250 mL) within 3 months prior to screening.
  12. Have participated in another drug trial within 3 months or in 3 or more clinical trials within the last year before the first dose of investigational drug; If the half-life of other investigational drugs is longer, the time interval required will be longer, suggesting 5 half-lives of the investigational drug.
  13. Blood donation including blood components or massive blood loss (≥ 200 mL) within 3 months prior to screening; patients who had blood transfusion or have used blood products.
  14. Have plan of giving birth or sperm donation within 90 days.
  15. Have received vaccine within 4 weeks prior to screening.
  16. Have taken any drugs that inhibit or induce hepatic metabolism of the drug within 28 days prior to taking the investigational drug [e.g., barbiturates, carbamazepine, phenytoin, , omeprazole; SSRI antidepressants, cimetidine, macrolides, nitroimidazoles, sedative hypnotics, fluoroquinolones, antihistamines, antiviral drugs (such as saquinavir, etc.), calcium antagonists (such as diltiazem, verapamil, etc.), rifamycins (such as rifampin, etc.)].
  17. Have taken prescription or over-the-counter medicine, dietary supplement or herbal remedy within 14 days prior to the first dose of investigational drug. If the half-life of the concomitant drug is longer, the time interval required will be longer, which is suggested as 5 half-lives of the investigational drug.
  18. Any abnormal result in laboratory tests and other examination, which is judged as clinical significance by the investigator.
  19. Have positive result in surface antigen, hepatitis B core antibody, antibody, (HIV) antibody, or Treponema pallidum antibody screening.
  20. Have abnormality in blood pressure, pulse and body temperature, reference to normal range (including boundary value): blood pressure 90-139/60-89 mmHg; pulse 60-100 bpm; body temperature (ear temperature) 35.4-37.7℃, the specific conditions would be comprehensively determined by the investigator.
  21. At screening, interval (corrected by Fridericia's formula, QTcF = QT/RR1/3) > 450 msec or QRS complex > 120 msec in 12-lead (ECG) resting on supine. If QTc exceeds 450 msec or QRS exceeds 120 msec, 2 additional ECG measurements should be repeated, and the subject's eligibility will be determined by using the average value of the 3 QTc or QRS measurements.
  22. Unwilling or unable to follow the lifestyle guideline described in the study protocol (e.g. dietary restrictions, activity and requirements).
  23. Have other acute or chronic medical or psychiatric disease that, in the judgment of the investigator, would make the subject unsuitable or increase the risk associated with participating in this study, or would interfere with interpretation of the study results.
  24. Have consumed chocolate, any caffeine-containing, xanthine-containing foods or beverages, and other special diets affecting the absorption, distribution, metabolism, and excretion of the drug during the admission period from screening to Day -2.
  25. Inability to keep abstinence from grapefruit or grapefruit-related citrus (e.g. pomelo) fruits or juices within 7 days prior to the first dose of study drug and for the duration of the study.
  26. Other subjects, judged by investigators, to be unsuitable for participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Arm 1 (IMP4297 100mg, Fasted-Fed)

    Period 1: Fasted control → Period 2: Fed control

    Drug: IMP4297

  • Experimental
    Arm 2(IMP4297 100mg, Fed- Fasted)

    Period 1: Fed control → Period 2: Fasted control

    Drug: IMP4297

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Peak Plasma Concentration

    Time frame: 2-month

  2. Tmax

    Time To Reach Maximum Concentration

    Time frame: 2-month

  3. AUC

    Area Under The Curve

    Time frame: 2-month

  4. t1/2

    Elimination Half-Life

    Time frame: 2-month

Secondary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

    Number of participants with treatment-related adverse events as assessed by CTCAE v4.03

    Time frame: 2-month

07

Study locations

1 site
  • Shanghai Public Health Clinical Center
    Shanghai, China
08

References and documents

Publications

  • Meng X, Lin X, Jiang R, Lu Y, Zeng L, Cao M, Zhang J. Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects. Clin Drug Investig. 2022 Nov;42(11):1009-1016. doi: 10.1007/s40261-022-01198-8. Epub 2022 Oct 14. PubMed 36239914 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Sep 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2019
First posted
Aug 15, 2019
StartActual
Jul 22, 2019
Primary completionActual
Sep 27, 2019
CompletionActual
Sep 27, 2019
Last update
Mar 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04057729
Lead sponsor
Impact Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 15, 2019
Start date
Jul 22, 2019
Primary completion
Sep 27, 2019
Completion
Sep 27, 2019
Last update
Mar 30, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Senaparib

Start the discussion